Serko First Half 2023 Earnings: NZ$0.17 loss per share (vs NZ$0.14 loss in 1H 2022)




  • In Business
  • 2022-11-25 18:11:00Z
  • By Simply Wall St.
 

Serko (NZSE:SKO) First Half 2023 Results

Key Financial Results

  • Revenue: NZ$18.8m (up 115% from 1H 2022).

  • Net loss: NZ$19.7m (loss widened by 30% from 1H 2022).

  • NZ$0.17 loss per share (further deteriorated from NZ$0.14 loss in 1H 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Serko Earnings Insights

Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Software industry in Oceania.

Performance of the market in New Zealand.

The company's shares are down 3.8% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Serko that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders have earned a 54% CAGR over the last three years
BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders have earned a 54% CAGR over the last three years

While BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) shareholders are probably generally happy, the stock hasn't had...

Here
Here's Why We Think Braemar (LON:BMS) Is Well Worth Watching

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Zoom to shed about 1,300 jobs as pandemic-fueled demand slows
Zoom to shed about 1,300 jobs as pandemic-fueled demand slows
  • US
  • 2023-02-07 17:35:33Z

Announcing the layoffs, Chief Executive Eric Yuan also said that he will take a salary cut of 98% for the coming fiscal year, foregoing his fiscal 2023...

Shareholders in Aadi Bioscience (NASDAQ:AADI) are in the red if they invested a year ago
Shareholders in Aadi Bioscience (NASDAQ:AADI) are in the red if they invested a year ago

Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...

SoftBank posts loss as Vision Fund in the red for fourth straight quarter
SoftBank posts loss as Vision Fund in the red for fourth straight quarter

TOKYO (Reuters) -SoftBank Group Corp on Tuesday booked a net loss for October-December, with its giant Vision Fund investment unit staying in the red for the...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business